Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116519 · ClinicalTrials.gov registry record · Phase 2
A Study in People With Abnormal Fat Levels in the Blood
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
NCT00116519: Completed Phase 2 study, sponsored by Eli Lilly and Company.
NCT00116519 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 300 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (126% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00116519, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
Study Summary
The purposes of this study are to determine: * The safety of the study medication and any side effects that might be associated with it; * Whether the study medication can help patients with low levels of 'good' cholesterol (HDL-C) and high blood fats or triglycerides (TG); * How much of the study medication should be given to patients; * How the study medication compares to fenofibrate (Lofibra), a drug used for people with low levels of HDL-C and high levels of TG.
Interventions
- DRUG placebo
- DRUG PPAR alpha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2005-07 |
| Est. Completion | 2006-10 |
| Phase | Phase 2 |
What the finished NCT00116519 record still lists
NCT00116519 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (126% higher).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00116519 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00116519 about?
NCT00116519 is a clinical study titled "A Study in People With Abnormal Fat Levels in the Blood". The purposes of this study are to determine: * The safety of the study medication and any side effects that might be associated with it; * Whether the study medication can help patients with low levels of 'good' cholesterol (HDL-C) and high blood fats or triglycerides (TG); * How much of the study ...
What is the current status of trial NCT00116519?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2005-07. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00116519?
The interventions under investigation include: placebo (DRUG), PPAR alpha (DRUG).
Who is sponsoring clinical trial NCT00116519?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00116519's enrollment target sits among peer trials
300 167th of 2000 higher than 1,813 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia